




## Supplementary




**Figure S1** Study inclusion flowchart. LUAD, lung adenocarcinoma.



**Figure S2** Association of GGO with (A) RFS and (B) CSS in patients with pathological stage IA3 LUAD. GGO, ground-glass opacity; RFS, recurrence-free survival; CSS, cancer-specific survival; LUAD, lung adenocarcinoma.



**Figure S3** Recurrence patterns in patients with pathological stage IA3 LUAD based on the presence or absence of a GGO component. GGO, ground-glass opacity; LUAD, lung adenocarcinoma.



**Figure S4** Association of GGO with recurrence pattern in patients with pathological stage IA3 LUAD according to MIP status [(A) MIP-positive patients; (B) MIP-negative patients]. GGO, ground-glass opacity; LUAD, lung adenocarcinoma; MIP, micropapillary.

**Table S1** Univariate and multivariate analysis of prognostic factors affecting patients with pathological stage IA3 LUAD

| Characteristics                 | RFS                  |         |                     |         | CSS                  |         |                      |         |
|---------------------------------|----------------------|---------|---------------------|---------|----------------------|---------|----------------------|---------|
|                                 | Univariable          |         | Multivariable       |         | Univariable          |         | Multivariable        |         |
|                                 | HR (95% CI)          | P value | HR (95% CI)         | P value | HR (95% CI)          | P value | HR (95% CI)          | P value |
| <b>Sex</b>                      |                      |         |                     |         |                      |         |                      |         |
| Female                          |                      |         |                     |         |                      |         |                      |         |
| Male                            | 2.733 (1.456–5.129)  | 0.002   | 1.608 (0.744–3.475) | 0.23    | 5.792 (2.217–15.135) | <0.001  | 4.020 (1.377–11.736) | 0.01    |
| <b>Age (years)</b>              |                      |         |                     |         |                      |         |                      |         |
| <65                             |                      |         |                     |         |                      |         |                      |         |
| ≥65                             | 1.099 (0.608–1.988)  | 0.76    |                     |         | 1.300 (0.640–2.642)  | 0.47    |                      |         |
| BMI (kg/m <sup>2</sup> )        | 1.002 (0.903–1.112)  | 0.97    |                     |         | 1.044 (0.920–1.184)  | 0.51    |                      |         |
| <b>Smoke history</b>            |                      |         |                     |         |                      |         |                      |         |
| No                              |                      |         |                     |         |                      |         |                      |         |
| Yes                             | 2.843 (1.585–5.098)  | <0.001  | 2.485 (1.200–5.144) | 0.01    | 3.728 (1.849–7.516)  | <0.001  | 2.112 (0.956–4.670)  | 0.07    |
| <b>Preoperative CEA (ng/mL)</b> |                      |         |                     |         |                      |         |                      |         |
| <5                              |                      |         |                     |         |                      |         |                      |         |
| ≥5                              | 1.151 (0.636–2.080)  | 0.64    |                     |         | 0.708 (0.333–1.504)  | 0.37    |                      |         |
| <b>Preoperative symptoms</b>    |                      |         |                     |         |                      |         |                      |         |
| No                              |                      |         |                     |         |                      |         |                      |         |
| Yes                             | 1.034 (0.557–1.918)  | 0.92    |                     |         | 0.726 (0.330–1.596)  | 0.43    |                      |         |
| Tumor size (cm)                 | 3.196 (0.951–10.739) | 0.06    |                     |         | 2.535 (0.518–12.396) | 0.25    |                      |         |
| Lymph node dissection           | 0.996 (0.960–1.034)  | 0.84    |                     |         | 1.000 (0.957–1.045)  | 0.99    |                      |         |
| <b>MIP component</b>            |                      |         |                     |         |                      |         |                      |         |
| <5%                             |                      |         |                     |         |                      |         |                      |         |
| ≥5%                             | 3.163 (1.773–5.642)  | <0.001  | 3.315 (1.830–6.003) | <0.001  | 3.306 (1.616–6.766)  | 0.001   | 3.723 (1.802–7.690)  | <0.001  |
| <b>GGO component</b>            |                      |         |                     |         |                      |         |                      |         |
| Absence                         |                      |         |                     |         |                      |         |                      |         |
| Presence                        | 0.200 (0.089–0.448)  | <0.001  | 0.232 (0.103–0.522) | <0.001  | 0.319 (0.131–0.779)  | 0.01    | 0.397 (0.161–0.977)  | 0.04    |
| <b>EGFR mutation</b>            |                      |         |                     |         |                      |         |                      |         |
| Negative                        |                      |         |                     |         |                      |         |                      |         |
| Positive                        | 0.954 (0.504–1.806)  | 0.89    |                     |         | 1.565 (0.678–3.610)  | 0.29    |                      |         |

LUAD, lung adenocarcinoma; RFS, recurrence-free survival; CSS, cancer-specific survival; HR, hazard ratio; CI, confidence interval; BMI, body mass index; CEA, carcinoembryonic antigen; GGO, ground-glass opacity; EGFR, epidermal growth factor receptor.

**Table S2** Univariate and multivariate analysis of prognostic factors affecting MIP-positive patients with pathological stage IA3 LUAD

| Characteristics          | RFS                  |         |                      |         | CSS                  |         |                      |         |
|--------------------------|----------------------|---------|----------------------|---------|----------------------|---------|----------------------|---------|
|                          | Univariable          |         | Multivariable        |         | Univariable          |         | Multivariable        |         |
|                          | HR (95% CI)          | P value |
| Sex                      |                      |         |                      |         |                      |         |                      |         |
| Female                   |                      |         |                      |         |                      |         |                      |         |
| Male                     | 2.061 (0.876–4.851)  | 0.10    |                      |         | 5.539 (1.560–19.673) | 0.008   | 3.438 (0.812–14.566) | 0.09    |
| Age (years)              |                      |         |                      |         |                      |         |                      |         |
| <65                      |                      |         |                      |         |                      |         |                      |         |
| ≥65                      | 0.764 (0.297–1.967)  | 0.58    |                      |         | 1.080 (0.366–3.187)  | 0.89    |                      |         |
| BMI (kg/m <sup>2</sup> ) | 1.169 (1.038–1.315)  | 0.01    | 1.084 (0.934–1.259)  | 0.29    | 1.171 (1.018–1.347)  | 0.03    | 1.101 (0.965–1.255)  | 0.15    |
| Smoke history            |                      |         |                      |         |                      |         |                      |         |
| No                       |                      |         |                      |         |                      |         |                      |         |
| Yes                      | 2.774 (1.153–6.669)  | 0.02    | 2.243 (0.754–6.674)  | 0.15    | 4.196 (1.491–11.811) | 0.007   | 2.023 (0.625–6.549)  | 0.24    |
| Preoperative CEA (ng/mL) |                      |         |                      |         |                      |         |                      |         |
| <5                       |                      |         |                      |         |                      |         |                      |         |
| ≥5                       | 0.660 (0.258–1.693)  | 0.39    |                      |         | 0.284 (0.064–1.261)  | 0.10    |                      |         |
| Preoperative symptoms    |                      |         |                      |         |                      |         |                      |         |
| No                       |                      |         |                      |         |                      |         |                      |         |
| Yes                      | 0.372 (0.125–1.104)  | 0.08    |                      |         | 0.451 (0.127–1.603)  | 0.22    |                      |         |
| Tumor size (cm)          | 9.618 (1.554–59.536) | 0.02    | 8.764 (1.387–55.372) | 0.02    | 5.017 (0.546–46.090) | 0.15    |                      |         |
| Lymph node dissection    | 1.027 (0.976–1.080)  | 0.31    |                      |         |                      |         |                      |         |
| GGO component            |                      |         |                      |         |                      |         |                      |         |
| Absence                  |                      |         |                      |         |                      |         |                      |         |
| Presence                 | 0.391 (0.132–1.157)  | 0.09    |                      |         | 0.801 (0.252–2.541)  | 0.71    |                      |         |
| EGFR mutation            |                      |         |                      |         |                      |         |                      |         |
| Negative                 |                      |         |                      |         |                      |         |                      |         |
| Positive                 | 1.080 (0.390–2.987)  | 0.88    |                      |         | 1.407 (0.367–5.393)  | 0.62    |                      |         |

MIP, micropapillary; LUAD, lung adenocarcinoma; RFS, recurrence-free survival; CSS, cancer-specific survival; HR, hazard ratio; CI, confidence interval; BMI, body mass index; CEA, carcinoembryonic antigen; GGO, ground-glass opacity; EGFR, epidermal growth factor receptor.